Jun 1, 2022 | Events, Homepage News, News, Uncategorized
In 2020, PRF checked off an important mission milestone: U.S. Food and Drug Administration (FDA) approval of lonafarnib (brand name Zokinvy®), the first-ever treatment for Progeria. Since then, and through tremendous effort and expense, PRF and partner Eiger...
May 20, 2022 | Homepage News, News, Uncategorized
May 20, 2022 – Eiger BioPharmaceuticals Inc. and The Progeria Research Foundation (PRF), announced today that Eiger has received a positive opinion from the CHMP recommending approval for Zokinvy, a breakthrough treatment for Hutchinson Gilford progeria...
May 4, 2022 | Homepage News, News, Uncategorized
In May 2022, The Progeria Research Foundation in partnership with Brigham and Women’s Hospital, and Boston Children’s Hospital will convene a specialized meeting of high-level cardiologists and researchers to discuss the urgency of cardiac stenosis in children with...
Feb 11, 2022 | Homepage News, Uncategorized
Happy Heart Health Month – and Happy Valentine’s Day! At PRF, we LOVE Heart Health Month – because treating and curing the heart disease that affects all children and young adults with Progeria is at the ‘heart’ of our mission. We hope you have a happy, healthy...
Nov 6, 2021 | Homepage News, News, Uncategorized
Workshop 2022 Registration Committee Agenda Speakers Speaker/Poster Abstract Submission Speakers’ Articles Hotel Reservations Location and Travel We’re starting our engines and revving up for The Progeria Research Foundation’s 11th International Scientific...
Sep 23, 2021 | Homepage News, News, Uncategorized
Check out our newsletter to read about FDA approval for the first-ever treatment for Progeria, learn how the research we fund has made remarkable progress toward the cure through genetic and RNA therapies, and get the scoop on all the exciting milestones we’re...
